The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE)

Authors

Daniel S. Hsia, Pennington Biomedical Research Center, Baton Rouge, LA, United States of America. Electronic address: grademail@bsc.gwu.edu.
Naji Younes, The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Heidi Krause-Steinrauf, The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, United States of America.
Laure Sayyed Kassem, Endocrine Section, Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, United States of America; Division of Clinical and Molecular Endocrinology, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States of America.

Document Type

Journal Article

Publication Date

3-1-2024

Journal

Journal of diabetes and its complications

Volume

38

Issue

3

DOI

10.1016/j.jdiacomp.2024.108692

Keywords

Clinical trial; Diabetes mellitus type 2; Diabetic retinopathy; Glycemic control; Patient reported outcome measures

Abstract

Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143.

APA Citation

Hsia, Daniel S.; Younes, Naji; Krause-Steinrauf, Heidi; and Kassem, Laure Sayyed, "The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE)" (2024). GW Authored Works. Paper 4283.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4283

Department

Biostatistics and Bioinformatics